Regeneron Pharmaceuticals, Inc. (REGN) drops on EYLEA pressure
April 29, 20266 min read
Key Takeaway
Regeneron Pharmaceuticals, Inc. (REGN) drops sharply after its Q1 2026 earnings report because investors are reacting to weakening EYLEA and EYLEA HD sales, not the headline beat on EPS and revenue. The company also cut full-year gross margin guidance, signaling more pressure on profitability. For investors, the move suggests the market is repricing Regeneron around franchise durability and margin quality rather than near-term earnings strength.
Regeneron Pharmaceuticals, Inc. (REGN) drops sharply today, falling 6.85% to $681.624 as of 3:04 p.m. ET while trading at 1.8x its 200-day average volume. The move stands out because it came after a quarter that beat on both earnings and revenue, which tells you investors are focused less on the headline beat and more on pressure inside Regeneron’s core eye-drug franchise and its margin outlook.
Key Takeaways
REGN is down 6.85% on above-average volume after reporting Q1 2026 earnings on April 29.
The main catalyst is an earnings-day reset: adjusted EPS came in at $9.47 versus $8.52 expected, and revenue rose 19% to $3.6B versus $3.4B expected, but investors focused on weaker EYLEA trends.
Combined U.S. EYLEA and EYLEA HD sales fell 10% to $941M, hurt by competition, lower selling prices, and the transition to EYLEA HD.
Regeneron also cut full-year 2026 GAAP gross margin guidance to 77%-78% from 79%-80%, citing manufacturing disruption impact.
For investors, the stock’s drop shows that product durability and margin quality matter more than a simple earnings beat, even for a biotech with strong Dupixent growth and a modest 17.6 P/E.
Why Regeneron Pharmaceuticals Inc. Stock Drops After Q1 Earnings
The clearest reason for today’s selloff is Regeneron’s Q1 2026 earnings report. On the surface, the quarter looked strong. Adjusted EPS was $9.47, above the $8.52 consensus, and revenue reached $3.6B, ahead of the $3.4B estimate. Total revenue also climbed 19% from a year earlier.
However, stocks do not trade on headlines alone. They trade on what the quarter says about future earnings power. In Regeneron’s case, the market zeroed in on weakness in EYLEA and EYLEA HD, the company’s retina franchise, which has long been a major profit engine.
Combined U.S. net sales of EYLEA and EYLEA HD fell 10% to $941M. Regeneron said the decline reflected continued competitive pressures, the transition to EYLEA HD, and lower net selling prices. Reuters also pointed to lower wholesaler inventory levels and regulatory complexities for the pre-filled syringe version of Eylea HD. That is the sort of detail that can spoil an otherwise good quarter fast.
There was also another concrete negative. Regeneron cut full-year 2026 GAAP gross margin guidance to 77%-78% from 79%-80% because of manufacturing disruption impact. When a company beats in the quarter but trims a key profitability guide, the market often treats that as a warning shot.
EYLEA Weakness and Margin Pressure Matter More Than the EPS Beat
This reaction makes sense when you look at how Regeneron is valued. REGN trades at a P/E of 17.6373, which is not stretched for a profitable biotech with a $70.82B market cap and EPS of 41.49. In other words, this was not a bubble stock waiting for an excuse to crack. The drop is more about changing confidence in the earnings mix.
Dupixent remains a major strength. Global net sales recorded by Sanofi rose to $4.88B from $3.67B a year earlier, up 33%. That growth helped drive Regeneron’s 15% increase in non-GAAP diluted EPS and supported the company’s broader immunology story.
Still, the market is treating Dupixent strength as old good news and EYLEA pressure as new bad news. That is a familiar pattern in biotech. A company can post a beat, but if one of its core franchises looks less durable, investors quickly reset the multiple. Plain English: the market is questioning the quality of the beat, not the existence of it.
The margin cut adds to that concern. Lower gross margin guidance means future profits face more pressure even if revenue holds up. For a business that already faces biosimilar and competitive risks in eye care, that change matters.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Regeneron Financials Still Show Strength Beneath Today’s Selloff
Today’s decline does not erase the fact that Regeneron remains financially solid. The company has beaten EPS estimates in 6 of the last 8 quarters. Before today, analysts had generally been constructive, with a Buy consensus and a median price target of $873. Recent targets included $910 from Raymond James on April 22 and $796 from Morgan Stanley on April 10.
Capital returns also offer support. Regeneron authorized a new $3.0B share repurchase program in April and bought back $803M of stock during the quarter. That does not stop a one-day selloff, but it does show management is still deploying capital from a position of strength.
The stock’s sentiment backdrop had also been strong coming into the report. News sentiment scores were firmly positive over the last 7, 30, and 90 days. That matters because it raises the bar. When sentiment is already strong, investors punish any crack in the story more aggressively. A good quarter is not enough if the market expected a cleaner one.
Even after the drop, REGN sits well above its 52-week low of $474.6009, though it is also meaningfully below its 52-week high of $820.1235. That range tells a simple story: investors still respect the business, but they are repricing the retina franchise risk.
What Today’s REGN Volume Spike Means for Investors
The 1.8x relative volume matters because it signals conviction behind the move. This is not a sleepy biotech drifting lower with the tape. It is a high-volume response to a specific event, and that event is earnings.
There is also a secondary backdrop worth noting. On April 23, Regeneron announced an agreement with the U.S. government tied to lowering drug costs for American patients. That policy angle was not the primary same-day driver, but it adds another layer of pressure around pricing and profitability.
At the same time, Regeneron still has real offsets. Dupixent won U.S. approval on April 22 as the first biologic for young children with chronic spontaneous urticaria, and EYLEA HD won an FDA approval on April 2 for dosing intervals up to every 20 weeks in certain eye diseases. Those are meaningful positives. Yet today’s market action says near-term investors care more about sales erosion and margin compression than fresh product wins.
Actionably, this looks like a stock that now needs proof that EYLEA HD can stabilize the retina business and that margin pressure stays contained. The valuation is no longer demanding, but a lower multiple alone is not a catalyst. In biotech, cheap can stay cheap when a core franchise is under attack.
For shorter-term traders, the lesson is straightforward: earnings beats do not help when the market dislikes the underlying mix. For longer-term investors, the setup is more nuanced. Strong Dupixent growth, buybacks, and a Buy-side analyst base still support the broader case, but today’s drop shows that REGN is being judged on franchise durability, not just quarterly arithmetic.
Regeneron’s stock is falling today because investors looked past the Q1 beat and focused on weaker EYLEA trends and lower gross margin guidance. That combination matters more than a headline EPS win, especially in a large biotech where product durability drives valuation.
The business still has clear strengths, led by Dupixent growth and aggressive buybacks. Even so, today’s heavy-volume selloff says the market wants firmer evidence that Regeneron can defend its retina franchise while protecting profitability.
REGN is down because investors focused on weaker EYLEA and EYLEA HD sales and a cut to full-year gross margin guidance. The earnings beat was not enough to offset concerns about the durability of Regeneron’s core eye-drug franchise.
+Should I buy REGN stock now?
The stock looks more attractive on valuation after the drop, but the key risk is whether EYLEA can stabilize and margins can hold up. Based on this report, investors may want to wait for clearer evidence that the franchise pressure is easing.
+Did Regeneron beat earnings expectations?
Yes, Regeneron beat both earnings and revenue estimates for the quarter. Even so, the stock fell because the market cared more about weaker product trends and lower margin guidance.
+What is the main risk for Regeneron investors right now?
The main risk is continued pressure on the EYLEA franchise, which has been a major profit driver. If sales keep slipping and margins stay under pressure, the stock could remain range-bound even with strong growth elsewhere.
Want the full picture on REGN?
Read the analyst-grade research report — charts, grades, and price targets.
